GH
GHRS.US GH Research PLC
- Market cap
- USD 1.31B
- P/E
- -
- P/B
- 3.53x
- ROE
- -19.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GHRS.US undervalued?
Graham numberThe Graham number of GH Research PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GH Research PLC fundamental analysis
No fundamental analysis for GH Research PLC yet.
GH Research PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebu…
Full company profileGH Research PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GH Research PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -19.0K | -47.0K | -315K | -315K | -335K | - |
| Operating Income | -310K | -446K | -15.1M | -30.6M | -41.2M | -50.3M | -60.7M | -76.4M |
| EBITDA | -310K | -445K | -9.17M | -22.4M | -35.2M | -38.6M | -47.5M | -67.7M |
| Net Income | -310K | -446K | -9.20M | -22.5M | -35.6M | -39.0M | -48.3M | -68.2M |
| EPS | -0.01 | -0.01 | -0.18 | -0.43 | -0.68 | -0.75 | -0.79 | -1.03 |
| Balance Sheet | ||||||||
| Total Assets | 504K | 5.91M | 280M | 254M | 226M | 188M | 288M | 372M |
| Total Liabilities | 104K | 246K | 2.75M | 4.55M | 7.33M | 9.32M | 8.53M | 12.9M |
| Shareholders' Equity | 400K | 5.67M | 277M | 250M | 219M | 179M | 280M | 359M |
| Cash & Short-term Investments | 498K | 5.90M | 277M | 166M | 162M | 149M | 281M | 363M |
| Total Debt | - | - | - | - | 974K | 624K | 512K | 360K |
| Cash Flow | ||||||||
| Operating Cash Flow | -289K | -330K | -15.3M | -26.2M | -33.3M | -42.3M | -43.6M | -51.4M |
| Capital Expenditure | 104K | 21.0K | 104K | 67.0K | 100K | 49.0K | 121K | 160K |
| Free Cash Flow | -289K | -330K | -15.4M | -26.3M | -33.4M | -42.3M | -43.7M | -51.5M |
| Ratios | ||||||||
| ROE | -77.5% | -7.9% | -3.3% | -9.0% | -16.3% | -21.8% | -17.3% | -19.0% |
| ROA | -61.5% | -7.5% | -3.3% | -8.8% | -15.7% | -20.7% | -16.7% | -18.3% |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
GH Research PLC dividends
GH Research PLC has not paid dividends in the last 7 fiscal years.
Who owns GH Research PLC
- Insiders 24.97%
- Institutions 74.20%
- Public & others 0.83%
- Shares outstanding 68.6M
- Free float 32.4M
Top funds holding GHRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 1.93M | 2.82% | +1.99% | Aug 2026 |
| Fidelity Growth Company K6 | 627K | 0.91% | +1.70% | Aug 2026 |
| Fidelity Series Growth Company | 485K | 0.71% | +1.76% | Aug 2026 |
| iShares Biotechnology ETF | 397K | 0.58% | -0.19% | Oct 2026 |
| Fidelity Select Biotechnology | 178K | 0.26% | +2.88% | Aug 2026 |
| BNY Mellon Sm/Md Cp Gr I | 137K | 0.20% | -1.86% | Sep 2026 |
| Artisan International Small-Mid Investor | 94.0K | 0.14% | 0.00% | Sep 2026 |
| AdvisorShares Psychedelics ETF | 92.0K | 0.13% | 0.00% | Oct 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 58.8K | 0.09% | +0.20% | Oct 2026 |
| iShares MSCI Ireland ETF | 53.3K | 0.08% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 40.5K | 0.06% | 0.00% | Aug 2026 |
| Premier Miton Diversified GrB Inc | 33.6K | 0.05% | -4.00% | Sep 2026 |
| TEQ - Disruptive Technologies - I-II | 31.0K | 0.05% | -1.49% | Sep 2026 |
| Manulife GF Healthcare AA | 29.3K | 0.04% | 0.00% | Sep 2026 |
| Arrow Long/Short Alt Fd F | 19.4K | 0.03% | 0.00% | Sep 2026 |
| Arrow Opportunities Alternative Series F | 19.4K | 0.03% | 0.00% | Sep 2026 |
| Premier Miton Global Leaders C Acc | 12.7K | 0.02% | +0.79% | Sep 2026 |
| Virtus Biotech Clinical Trials ETF | 12.7K | 0.02% | 0.00% | Oct 2026 |
| BNY Mellon Small Cap Multi-Strategy M | 11.5K | 0.02% | -1.17% | Sep 2026 |
| Truvalue Glb Phrmctl Blgcl Eq (QDII) A | 11.0K | 0.02% | 0.00% | Jun 2026 |
Top institutions holding GHRS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Lynx1 Capital Management, LP | 13.3M | 19.32% | +23.23% | Jun 2026 |
| Bvf Inc | 8.65M | 12.60% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 7.64M | 11.13% | -0.52% | Jun 2026 |
| FMR Inc | 5.98M | 8.71% | +16.37% | Jun 2026 |
| RTW INVESTMENTS, LLC | 5.93M | 8.64% | 0.00% | Jun 2026 |
| Deep Track Capital, LP | 3.33M | 4.86% | 0.00% | Jun 2026 |
| venBio Select Advisor LLC | 1.80M | 2.62% | 0.00% | Jun 2026 |
| Foresite Capital Management VI LLC | 940K | 1.37% | +198.10% | Jun 2026 |
| Jefferies Financial Group Inc | 712K | 1.04% | 0.00% | Jun 2026 |
| BlackRock Inc | 480K | 0.70% | +5.41% | Jun 2026 |
| UBS Group AG | 477K | 0.70% | +15.76% | Jun 2026 |
| Millennium Management LLC | 323K | 0.47% | -65.52% | Jun 2026 |
| BRAIDWELL LP | 207K | 0.30% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 202K | 0.29% | -28.56% | Jun 2026 |
| Jane Street Group LLC | 170K | 0.25% | 0.00% | Jun 2026 |
| HighVista Strategies LLC | 159K | 0.23% | -25.53% | Jun 2026 |
| Trexquant Investment LP | 154K | 0.22% | +120.27% | Jun 2026 |
| The Goldman Sachs Group Inc | 149K | 0.22% | +231.90% | Jun 2026 |
| XTX Topco Ltd | 87.0K | 0.13% | +66.99% | Jun 2026 |
| Citadel Advisors Llc | 86.0K | 0.13% | +31.30% | Jun 2026 |
GH Research PLC company profile
- Company name
- GH Research PLC
- Ticker
- GHRS.US
- ISIN
- IE000GID8VI0
- Exchange
- USA Stocks
- Listed since
- Jun 25, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Fiscal year end
- December
- Address
- Joshua Dawson House, Dublin, Ireland, D02 RY95
- Phone
- 353 1 437 8334
- Website
- ghres.com
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
GH Research PLC management
5- Mr. Florian Schonharting M.Sc. (Econ)Co-Founder & Non-Executive Chairman of the Board · born 1969
- Dr. Velichka Valcheva M.D., M.Sc.Chief Executive Officer · born 1975
- Mr. Magnus HalleCo-Founder & MD of Ireland · born 1997
- Ms. Julie Ryan F.C.A.Vice President of Finance · born 1986
- Mr. Aaron Cameron M.B.A.Chief Operating Officer · born 1985